Background: Nitric oxide (NO)-related biomarkers, including asymmetric dimethylarginine (ADMA), nitric oxide (NO), and endothelial nitric oxide synthase (eNOS), may play a role in the pathophysiology and clinical progression of chronic obstructive pulmonary disease (COPD). This study aimed to investigate their diagnostic value in stable COPD and acute exacerbation. Methods: A total of 150 participants (76 females, 74 males; mean age 53.82 ± 7.06 years) were enrolled and equally distributed into control, stable COPD, and acute exacerbation groups (n = 50 each). Demographic, clinical, and laboratory parameters were compared across groups. Serum ADMA, NO, and eNOS levels were analyzed, and correlations with clinical findings were evaluated. ROC analysis was performed to determine the diagnostic performance of the biomarkers. Results: Serum ADMA levels were significantly higher in COPD patients, particularly in the acute exacerbation group (p < 0.05 for all comparisons). In contrast, NO and eNOS levels were significantly lower in COPD groups compared to controls (p < 0.05 for all comparisons). ADMA showed strong negative correlations with FEV1, FEV1/FVC, PaO2, and SaO2, whereas NO and eNOS showed positive correlations with the same parameters (all p < 0.01). For predicting acute exacerbation, an ADMA cut-off of 1.36 yielded high diagnostic accuracy (AUC = 0.983; sensitivity 86.0%; specificity 96.0%). eNOS also demonstrated predictive value (AUC = 0.823). For stable COPD, NO at a cut-off of 14.91 showed excellent diagnostic performance (AUC = 0.921). Conclusions: NO-related biomarkers, particularly ADMA and NO, may serve as reliable indicators for differentiating between stable COPD and acute exacerbation. Elevated ADMA and reduced NO and eNOS levels were closely associated with impaired lung function and oxygenation parameters. These findings suggest potential clinical utility of these biomarkers in COPD monitoring and management.
Background: Biomarkers reflecting innate immune activation may complement clinical severity scores in community-acquired pneumonia (CAP). This study evaluated serum presepsin and pentraxin-3 (PTX3) concentrations in patients with CAP and healthy controls and examined their associations with pneumonia severity. Methods: Ninety participants were analyzed, including 45 patients with CAP and 45 healthy controls. Pneumonia severity was assessed using the Pneumonia Severity Index (PSI) and CURB-65. Group comparisons, Spearman correlation analyses, receiver operating characteristic (ROC) analyses, and an exploratory multivariable logistic regression model were performed. Results: Presepsin concentrations were higher in patients with CAP than in healthy controls (2157 [1824–2524] vs. 1749 [1652–1879] pg/mL; p < 0.001), as were PTX3 concentrations (2.15 [1.76–2.87] vs. 1.67 [1.40–2.11] ng/mL; p < 0.001). For discrimination of CAP from healthy controls, the AUC was 0.822 (95% CI 0.728–0.902) for presepsin and 0.706 (95% CI 0.598–0.810) for PTX3. Among patients with CAP, presepsin correlated with PSI (rho = 0.552, p < 0.001) and CURB-65 (rho = 0.600, p < 0.001), while PTX3 showed stronger correlations with PSI (rho = 0.691, p < 0.001) and CURB-65 (rho = 0.668, p < 0.001). For identifying PSI classes IV–V, the AUC was 0.647 for presepsin and 0.742 for PTX3. Conclusions: Both presepsin and PTX3 were elevated in CAP and were associated with increasing disease severity. Within this pilot sample, presepsin showed a numerically higher AUC for discrimination between CAP and healthy controls, whereas PTX3 showed stronger associations with severity. Larger prospective studies are required to validate these findings.